Clinical Trial Update: Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating dexmedetomidine for light to moderate sedation in palliative COVID-19 patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Infection
• Respiratory Failure

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: University Hospital, Limoges | Conditions: COVID-19 Infection, Sars-cov-2 | Phase 4 | Status: WITHDRAWN